Roche Holding AG (OTCMKTS:RHHBY) Receives $40.00 Consensus Target Price from Brokerages

Shares of Roche Holding AG (OTCMKTS:RHHBY) have been given a consensus recommendation of “Hold” by the seven ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $40.00.

Several research firms have issued reports on RHHBY. Argus reaffirmed a “hold” rating on shares of Roche in a report on Monday, March 4th. Deutsche Bank Aktiengesellschaft raised Roche from a “sell” rating to a “hold” rating in a report on Friday, May 17th.

Institutional Investors Weigh In On Roche

Several hedge funds have recently bought and sold shares of the stock. AlphaMark Advisors LLC acquired a new stake in shares of Roche in the first quarter valued at approximately $34,000. Wetzel Investment Advisors Inc. acquired a new stake in shares of Roche in the fourth quarter valued at approximately $53,000. Operose Advisors LLC acquired a new stake in shares of Roche in the third quarter valued at approximately $59,000. First Horizon Advisors Inc. raised its position in shares of Roche by 19.8% in the fourth quarter. First Horizon Advisors Inc. now owns 2,066 shares of the company’s stock valued at $75,000 after buying an additional 342 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new position in Roche during the fourth quarter valued at approximately $146,000.

Roche Price Performance

Shares of RHHBY opened at $31.67 on Monday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.35 and a quick ratio of 1.04. Roche has a one year low of $29.20 and a one year high of $40.48. The business’s 50 day simple moving average is $31.06 and its 200-day simple moving average is $33.27.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.